Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study

NCT02949570 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

CML, Chronic Phase

Interventions

DRUG: Inecalcitol

Sponsor

Hybrigenics Corporation